Get the Stockscreener App
10.47
3.68%
-0.40
Rocket Pharmaceuticals Inc stock is traded at $10.47, with a volume of 1.07M.
It is down -3.68% in the last 24 hours and up +3.05% over the past month.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
See More
Previous Close:
$10.87
Open:
$10.99
24h Volume:
1.07M
Relative Volume:
0.76
Market Cap:
$1.11B
Revenue:
-
Net Income/Loss:
$-258.08M
P/E Ratio:
-3.8073
EPS:
-2.75
Net Cash Flow:
$-202.32M
1W Performance:
+0.00%
1M Performance:
+3.05%
6M Performance:
-47.65%
1Y Performance:
-63.31%
1-Day Range:
$10.42
$11.08
1-Week Range:
$10.42
$11.11
52-Week Range:
$9.33
$31.47
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
10.47 | 1.11B | 0 | -258.08M | -202.32M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | Wedbush | Outperform |
| Dec-18-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-01-23 | Initiated | Morgan Stanley | Overweight |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Nov-01-22 | Initiated | BTIG Research | Buy |
| Jul-08-22 | Initiated | Raymond James | Outperform |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Feb-18-21 | Initiated | Needham | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-02-20 | Initiated | JP Morgan | Overweight |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-26-19 | Initiated | Piper Jaffray | Overweight |
| Apr-23-19 | Initiated | Robert W. Baird | Outperform |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Feb-05-19 | Initiated | Oppenheimer | Outperform |
| Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
| Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
Rocket Pharmaceuticals (RCKT) Projected to Post Quarterly Earnings on Monday - Defense World
Long Term Trading Analysis for (RCKT) - Stock Traders Daily
2 Soaring Stocks to Hold for the Next 20 Years - The Globe and Mail
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Hits New 52-Week LowHere's Why - MarketBeat
Sovran Advisors LLC Acquires New Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
RCKT stock touches 52-week low at $9.76 amid market challenges - MSN
Strategic Financial Concepts LLC Takes Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharma Is A Buy At These Prices With Promising Data (NASDAQ:RCKT) - Seeking Alpha
Jennison Associates LLC Purchases 29,564 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
It makes sense and dollars to buy Rocket Pharmaceuticals Inc (RCKT) stock - SETE News
(RCKT) Long Term Investment Analysis - Stock Traders Daily
Rocket Pharmaceuticals Inc (RCKT) Shares Plummet Below 1-Year High - The News Heater
What was Rocket Pharmaceuticals Inc (RCKT)’s performance in the last session? - US Post News
Holdings of Rocket Pharmaceuticals Inc (RCKT) are aligned with the stars - SETE News
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Purchased by SG Americas Securities LLC - MarketBeat
SG Americas Securities LLC Acquires 48,793 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals appoints new board member By Investing.com - Investing.com Nigeria
Rocket Pharmaceuticals appoints new board member - Investing.com
Rocket Pharmaceuticals, Inc. Announces Board Changes -January 28, 2025 at 06:03 am EST - Marketscreener.com
Rocket Pharmaceuticals vice president sells $9,300 in stock - MSN
(RCKT) Technical Pivots with Risk Controls - Stock Traders Daily
Rocket Pharmaceuticals vice president sells $9,300 in stock By Investing.com - Investing.com Australia
Leerink Partnrs Has Strong Forecast for RCKT FY2024 Earnings - Defense World
FY2024 Earnings Estimate for RCKT Issued By Leerink Partnrs - MarketBeat
Analysts Offer Predictions for RCKT FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts RCKT FY2025 Earnings - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 52-Week LowHere's What Happened - MarketBeat
Analysts Set Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Price Target at $47.27 - MarketBeat
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Hexcel (NYSE:HXL) Reports Sales Below Analyst Estimates In Q4 Earnings - The Globe and Mail
RCKT stock touches 52-week low at $10.11 amid market challenges - MSN
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 12-Month Low – Time to Sell? - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Down 4%Here's Why - MarketBeat
How to Take Advantage of moves in (RCKT) - Stock Traders Daily
Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Acquired by Mirador Capital Partners LP - MarketBeat
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):